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Abstract
Background: Female genital schistosomiasis (FGS) is a neglected tropical gynaecological disease that affects
millions of women in sub-Saharan Africa (SSA). FGS is caused by Schistosoma haematobium, a parasitic carcinogen
involved in the pathogenesis of squamous cell carcinoma of the bladder. Cervical cancer incidence and mortality
are highest in SSA, where pre-cancerous cervical dysplasia is often detected on screening with visual inspection
with acetic acid (VIA). There are no studies evaluating the association between VIA positivity and FGS diagnosed by
genital PCR.
Methods: Women were recruited from the Bilharzia and HIV (BILHIV) study in Zambia a community-based study
comparing genital self-sampling to provider obtained cervicovaginal-lavage for the diagnosis of FGS in women
aged 18–31. FGS was defined as positive Schistosoma DNA from any genital PCR. Urogenital schistosomiasis
diagnostics included urine circulating anodic antigen, urine microscopy and portable colposcopy. Participants were
offered cervical cancer screening using VIA at Livingstone Central Hospital. Associations of PCR confirmed FGS and
other diagnostics with VIA positivity were assessed using multivariable logistic regression.
Results: VIA results were available from 237 BILHIV participants. A positive Schistosoma PCR in any genital specimen
was detected in 14 women (5.9%), 28.6% (4/14) of these women had positive VIA compared to 9.0% without PCR
evidence of schistosome infection (20/223). Schistosoma PCR positivity in any genital specimen was strongly
associated with VIA positivity (OR: 6.08, 95% CI: 1.58–23.37, P = 0.02).
Conclusions: This is the first study to find an association between FGS and positive VIA, a relationship that may be
causal. Further longitudinal studies are needed.
Keywords: Female genital schistosomiasis, Cervical dysplasia, Schistosoma haematobium, PCR, Urogenital
schistosomiasis
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Introduction
Female genital schistosomiasis (FGS) is a neglected para-
sitic gynaecological disease that affects an estimated 56
million women in sub-Saharan Africa [1, 2]. It is most
commonly caused by Schistosoma haematobium, blood
flukes which lay eggs in the vesical plexus [2]. These
eggs become entrapped in the urogenital mucosa result-
ing in inflammation and reproductive morbidity [3]. Cer-
vical cancer is a leading cause of cancer-related deaths
in African women [4–6]. In Zambia age-standardised in-
cidence rates of cervical cancer are 63.3 per 100,000 with
a mortality rate of 41.1 per 100,000, over 10 times that
of the United States of America [4]. S. haematobium in-
fection causes squamous cell carcinoma (SCC) of the
bladder, therefore a role in cervical cancer pathogenesis
is plausible [7]. This is a prescient prospect given the re-
cent launch by WHO of a global initiative to eliminate
cervical cancer by 2030 [8].
In the absence of a reference standard, making an FGS
diagnosis can be challenging and often requires the use
of multiple diagnostic modalities. FGS is associated with
typical genital mucosal visible lesions, however parasite
eggs can be found in macroscopically normal tissue [9,
10]. Sandy patches (grainy and homogenous) and abnor-
mal blood vessels have been associated with S. haemato-
bium eggs on pap smear [11]. Cervicovaginal lavage
(CVL) or genital swabs can be used to detect Schisto-
soma DNA by PCR [12, 13]. Community-based ap-
proaches have shown that FGS diagnosis using self-
collected cervical and vaginal swabs is acceptable to par-
ticipants, has comparable sensitivity to CVL [12], and
provides an objective alternative to imaging [14]. Urine
microscopy for eggs or the detection of circulating an-
odic antigen (CAA) can diagnose active schistosome in-
fection, but do not necessarily reflect genital
involvement [12, 15].
Pre-cancerous stages of cervical cancer are treatable
and can be detected with screening [16]. Human papillo-
mavirus (HPV) testing is WHO-recommended for cer-
vical screening as HPV infection is the most common
cause of cervical cancer [17]. In resource-constrained
settings where HPV testing is available, visual inspection
with acetic acid (VIA) can be used to visualise pre-
cancerous lesions [18]. In a large meta-analysis of 32
studies, including 18 in low and middle income coun-
tries, VIA was found to be less sensitive (0.69 vs. 0.95),
but more specific (0.87 vs. 0.84) than HPV testing for
the detection of cervical in situ neoplasia grade 2–3 as
diagnosed by colposcopy with or without biopsy [19].
Identified lesions are treated with cryotherapy or loop
electrosurgical excision procedure (LEEP). The co-
existence of FGS and cervical malignancy is well-
documented in pathology reports [20, 21], and
homogenous sandy patches have been associated with
the presence of high risk HPV [22]; however, this associ-
ation is not universally reported [23]. This study aimed
to evaluate the association between FGS and cervical
dysplasia diagnosed by VIA in Zambian women.
Materials and methods
This study was a community based cross-sectional study.
Data previously collected for the bilharzia and HIV study
(BILHIV) and stored in clinical records were analysed
retrospectively.
Participant recruitment
Between January and August 2018, 18–31 year-old, non-
pregnant, sexually active participants in two schistosom-
iasis low-endemic communities in Zambia were con-
secutively recruited after the 36-month HPTN 071
(PopART) study visit to the bilharzia and HIV (BILHIV)
study [12, 24].
Following informed consent, BILHIV study partici-
pants self-collected a urine sample, and cervical and va-
ginal swabs, as previously described [12]. During clinic
follow-up at the cervical cancer clinic at Livingstone
Central Hospital, midwives performed CVL and portable
colposcopy (MobileODT, Tel Aviv, Israel) to capture im-
ages of vagina and cervix [12].
Cervicovaginal images were evaluated by one medically
trained reviewer and classified as suggestive of ‘visual
FGS’ if homogenous sandy patches, grainy sandy
patches, rubbery papules, or abnormal blood vessels
were present, and negative if none were present [25].
Women with evidence of schistosome infection by any
diagnostic, or by midwife’s clinical examination [25]
were treated with 40 mg/kg praziquantel as recom-
mended by WHO [25]. Participants with suspected sexu-
ally transmitted infections (STI) were offered syndromic
management, as per Ministry of Health guidelines [26].
Routine STI testing was not performed at the point-of-
care in this study. Laboratory-based fourth-generation
HIV-1 testing (Abbott Architect HIV Ag/Ab Combo
Assay, Wiesbaden, Germany) was performed for HPTN
071 (PopART) participants at each study visit [24].
Visual inspection with acetic acid
Due to high community HIV prevalence [27], all women
regardless of age, are routinely offered cervical cancer
screening with VIA at the Cervical Cancer Clinic (CCC),
in Livingstone Central Hospital by the Zambian Health
Service. For those women that wished to be screened for
cervical cancer and after CVL was obtained for the BIL-
HIV study, 3–5% acetic acid was applied to the cervix.
An opaque white reaction was classified as positive and
no change was negative [18]. VIA results were docu-
mented in the clinical records at the CCC and were not
collected as part of BILHIV. In line with national and
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local clinic protocols adapted to real-world resource lim-
itations, HPV testing was not performed. Later, data
matching was performed to identify BILHIV participants
that had also attended the CCC for cervical cancer
screening. All BILHIV participants with an available VIA
result from routine Zambia Health Service screening
were included if data could be matched from both
sources.
Schistosoma diagnostics
DNA isolation was performed at Leiden University Med-
ical Center (LUMC), followed by real time-PCR for the
detection of Schistosoma DNA, as previously described
[12, 28, 29]. CAA quantification was performed using an
up-converting reporter particle lateral flow assay (UCP-
LF) at LUMC [30]. Analysing the equivalent of 417 μL
urine, a CAA value of > 0.6 pg/mL was considered posi-
tive based on a series of negative controls (highest value
plus 2 SDs) [30].
This study involved retrospective analysis of data col-
lected for previously published work from the BILHIV
study [12]. VIA data were collected from existing clinical
records. No additional participant participation was
required.
Ethics
Ethical approval was granted by London School of Hy-
giene and Tropical Medicine (LSHTM) (reference 16,
451) and University of Zambia Biomedical Research Eth-
ics Committee (reference: 011–08-17). The Livingstone
Central Hospital Superintendent gave permission to
conduct the study.
Statistical methods
Cervical dysplasia diagnosed by VIA was the dependent
variable. Univariable logistic regression analysis was carried
out to calculate crude odds ratios for associations between
VIA and all exposure variables; multivariable logistic regres-
sion analysis was used to calculate adjusted odds ratios for
associations between VIA and FGS variables controlling for
age category and HIV status as a priori confounders. No
further potential confounders could be included due to the
small number of women with positive VIA. P-values were
generated using likelihood ratio tests. All data were ana-
lysed using STATA 15 [31].
Results
A total of 237/527 (44.9%) women from the BILHIV
study also had VIA results available and were included
in the analysis (see Fig. 1).
The median age was 24 (IQR 22–27) and the majority
had some secondary education and were not currently
employed. All 24 women (10.1%) with positive VIA
(Table 1) were treated; 20 with cryotherapy (83.3%) and
4 with LEEP (16.7%). There was no association between
any demographic factors and VIA positivity (Table 2).
The prevalence of active S. haematobium infection
was 6.3% (15/237) by urine microscopy, and 14.8% (35/
237) by urine CAA (Table 1). Schistosoma PCR in any
genital specimen (CVL, cervical or vaginal swab) was
positive in 14/237 (5.9%). Relative proportions for each
FGS diagnostic being positive compared to all others are
represented in sup. Table 1. Colposcopy images were in-
terpretable in 216 women, of whom 70 had ‘visual FGS’
(29.5%). HIV-1 prevalence was 23.8% (56/235).
Of 14 women with positive Schistosoma PCR, 4 were
VIA positive (28.6%), compared to 20 of 223 with nega-
tive PCR (9.0%). The adjusted odds ratio for the associ-
ation between positive VIA and FGS diagnosed by
genital PCR was 6.08 (95% CI: 1.58–23.37) and there
was strong evidence for this association (P = 0.016).
There was no evidence for an association between VIA
positivity and ‘visual FGS’ (OR: 0.58, 95% CI: 0.20–1.69,
P = 0.30) or urine CAA/microscopy (OR 2.21, 95% CI
0.83–5.89, P = 0.13) (see Fig. 2). There was only one
Fig. 1 Participant recruitment of 237 women in the BILHIV study
who underwent VIA
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Table 1 Baseline characteristics and diagnostic test results amongst 237 participant women
Characteristics n (%)
Demography
Age (years) 18–22 64 (27.0)
23–26 91 (38.4)
27–31 82 (34.6)
Education None or primary 74 (31.2)
Secondary or higher 163 (68.8)
Employment Unemployed 163 (68.8)
Employed 74 (31.2)
Marital status Currently single 116 (49.0)
Currently married 121 (51.1)
Ever pregnant Never 36 (15.2)
Yes 201 (84.8)
Contraception Yes 183 (77.2)
No 54 (22.8)




HIV status*** Positive 56 (23.8)
Negative 179 (76.2)
HIV status self-reported**** Positive 42 (17.8)
Negative 194 (82.2)
HIV seroconversion during HPTN 071 *** Yes 5 (2.1)
No 230 (97.9)
Cervical dysplasia
VIA Positive 24 (10.1)
Negative 213 (89.9)





Genital Schistosoma PCR Positive 14 (5.9)
Negative 223 (94.1)
Imaging findings suggestive of FGS* Present 70 (29.5)
Absent 146 (61.6)
CAA** Positive 35 (14.8)
Negative 201 (84.8)
Urine microscopy Positive 15 (6.3)
Negative 222 (93.7)
*n = 216, 21 women with uninterpretable images; **n = 236, one urine vial arrived to LUMC empty; ***n = 235, 2 results missing from HPTN-271 (PopART)
database; ****n = 236, one woman declined to disclose status
Rafferty et al. BMC Infectious Diseases          (2021) 21:691 Page 4 of 9
Table 2 Number (n) and percentage (%) of study variables amongst the study population by VIA status
n (%) n (%) VIA+ Crude OR VIA+ 95% CI P-value
FGS by PCR n = 237 Positive 14 (5.9) 4 (28.6) 4.06 1.15–14.38 0.044
Negative 223 (94.1) 20 (9.0) 1
Visual FGS n = 216a Positive 70 (29.5) 5 (7.1) 0.63 0.22–1.79 0.364
Negative 146 (61.6) 16 (11.0) 1
CAA n = 236b Positive 35 (14.8) 5 (14.3) 0.55–4.62 0.428
Negative 201 (84.8) 19 (9.5) 1
Urine microscopy n = 237 Positive 15 (6.3) 3 (20.0) 2.39 0.62–9.23 0.237
Negative 222 (93.7) 21 (9.5) 1
Age n = 237 18–22 64 (27.0) 5 (7.8) 1 0.112
23–26 91 (38.4) 6 (6.6) 0.83 0.24–2.87
27–31 82 (34.6) 13 (15.9) 2.22 0.74–6.68
HIV status n = 235c Positive 56 (23.8) 8 (14.3) 1.7 0.68–4.23 0.265
Negative 179 (76.2) 16 (8.9) 1
District n = 237 Community A 142 (59.9) 15 (10.6) 1 0.785
Community B 95 (40.1) 9 (9.5) 0.89 0.37–2.12
Education n = 237 None or primary 74 (31.2) 11 (14.9) 1 0.113
Secondary or higher 163 (68.8) 13 (8.0) 0.5 0.21–1.18
Employment n = 237 Unemployed 163 (68.8) 15 (9.2) 1 0.490
Employed 74 (31.2) 9 (12.2) 1.37 0.57–3.29
Marital status n = 237 Currently single 116 (49.0) 14 (12.1) 1 0.331
Currently married 121 (51.1) 10 (8.3) 0.66 0.28–1.55
Ever pregnant n = 237 Never 36 (15.2) 20 (10.0) 0.88 0.28–2.76 0.834
Yes 201 (84.8) 4 (11.1) 1
Contraception n = 237 Yes 183 (77.2) 15 (8.2) 1 0.085
No 54 (22.8) 9 (16.7) 2.24 0.91–5.50
Condoms n = 237 Yes 47 (19.8) 6 (12.8) 1.4 0.52–3.75 0.514
No 190 (80.2) 18 (9.5) 1
Previous bilharzia diagnosis or treatment n = 237 Yes 29 (12.2) 3 (10.3) 1.09 0.30–3.94 0.630
Unsure 10 (4.2) 2 (20.0) 2.36 0.46–12.00
No 198 (83.5) 19 (9.6) 1
Abbreviations: CAA Circulating anodic antigen, CI Confidence interval, FGS female genital schistosomiasis, HIV Human immunodeficiency virus, OR odds ratio, PCR
polymerase chain reaction, VIA Visual inspection with acetic acid
a21 with uninterpretable images; bone urine vial arrived to LUMC empty; c2 results missing from HPTN-271 (PopART) database
Fig. 2 Forest Plot illustrating the results of a multivariable logistic regression of different FGS diagnostic methods and positive visual inspection
with acetic acid (VIA), odds ratios adjusted for age and HIV status
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woman who was both HIV-1 positive and FGS PCR
positive and therefore it was not possible to perform fur-
ther analysis. Of the 13 FGS positive women, 3 were
HIV-negative (23.0%), and of the 55 FGS negative
women 7 were HIV positive (12.7%).
Discussion
This study is the first to provide evidence for an associ-
ation between FGS and cervical dysplasia. These are two
common gynaecological conditions in SSA, which to-
gether lead to significant morbidity and mortality.
Chronic inflammation due to S. haematobium egg de-
position is thought to be on the causal pathway to blad-
der squamous cell carcinoma [7]. We hypothesize that
the inflammatory consequences of S. haematobium egg
deposition in FGS could similarly contribute to cervical
cancer pathogenesis (Fig. 3). Possible mechanistic syner-
gies with co-infections include FGS-related epithelial
disruption [32] allowing HPV to establish infection, and
the recruitment of immune cells that may influence the
interaction of HIV or HPV with cervical tissue. Add-
itionally, changes in local pro-inflammatory cytokines
may promote HPV persistence or transcription [33] and
a systemic Th2 environment may be associated with cer-
vical lesion progression [34]. Alternatively, there could
be confounders at the community level including access
to healthcare, health education and socio-economic fac-
tors. Of note, we did not find an association between
VIA and previous self-reported history of schistosomia-
sis. While participants may have been asymptomatic or
have limited access to diagnostics, we were unable to
confirm a previous diagnosis of bilharzia, and so this
variable is subject to recall bias. The possible association
between FGS and cervical dysplasia has important clin-
ical implications in endemic areas where FGS is not yet
considered a risk factor for cervical cancer [35]. If this
association is substantiated FGS diagnosis and treatment
could become an important component of cervical can-
cer prevention.
Several previous studies have investigated the associ-
ation between S. haematobium and cervical dysplasia.
However, heterogeneous methods in diagnosing both
the exposure (FGS) and the outcome (cervical dysplasia)
make cross-study comparisons challenging. In a South
African study, no association was found between FGS di-
agnosed by CVL PCR, or pap-smear and cervical dyspla-
sia diagnosed with cytology. However, over 97% of pap-
smears from women with FGS were uninterpretable,
limiting the sample size [23]. A population-based cross-
sectional study in Zimbabwe showed an association be-
tween the presence of typical FGS homogenous yellow
sandy patches and high-risk HPV [36]. After 5 years of
follow-up in this cohort, sandy patches were not associ-
ated with high risk HPV persistence or cervical dysplasia
but again, conclusions were limited by low power [22].
To our knowledge, VIA has not previously been used
for the diagnosis of cervical dysplasia in the context of
FGS. A meta-analysis found a pooled sensitivity of 78%
and specificity of 88% for CIN2+/high-grade squamous
intraepithelial lesion detection by VIA as compared to
Fig. 3 Conceptual pathway highlighting possible mechanisms linking female genital schistosomiasis and cervical dysplasia
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colposcopy [37], and was preferable in terms of re-
sources and availability [38]. In our cohort we found a
low uptake of cervical cancer screening (44.9%), which
has previously been demonstrated in Zambia [39]. This
may reflect known barriers to cervical cancer screening
such as limited health education and stigma [40]. Indeed,
a 2016 cross-sectional study in Lusaka, Zambia found
that only 36.8% of participants had heard of cervical can-
cer and only 20.7% of women had ever attended screen-
ing [41]. VIA has been extensively used in Zambia and
has been shown to be effective in reducing cervical can-
cer related mortality [42], and can be effectively scaled
up to reach a higher proportion of the population [43] .
This study included young women aged 18–31. There
is a lack of evidence surrounding age of initiation for
cervical screening, in part due to reduced cervical cancer
incidence in women under 25 [4], lesion regression in
younger women [44], and potential of harm with cervical
interventions [45]. Zambian guidelines suggest screening
initiation at 25 and WHO recommends screening HIV-
positive women regardless of age [46]. Due to high HIV
prevalence, all women presenting to Livingstone Central
Hospital are offered VIA screening [27]. Including only
younger women in this study may limit its generalisabil-
ity and further investigation including older women may
be required. Increased risk of cervical cancer in women
with HIV-1 is well documented [47] however, this study
was not powered to detect such an association. Our
study did not collect data on previous cervical cancer
screening, which is recommended for all HIV-1 positive
women [48]. It is therefore possible that HIV positive
women had previously been screened and treated.
Women in our study easily accessed the cervical can-
cer screening programme offered in the same clinic, il-
lustrating how FGS diagnostics could be integrated into
existing programmes. There is future potential for the
diagnosis and treatment of two common and morbid gy-
naecological conditions at a single clinic visit. Given the
cross-sectional study design, we cannot ascertain causal-
ity between FGS and cervical dysplasia. Lack of HPV
testing, and absence of tissue biopsy to confirm VIA re-
sults also limit our conclusions. A longitudinal study is
needed to investigate a temporal relationship between
FGS, HPV, and cervical dysplasia across age groups and
geographic locations. Mechanistic studies are also
needed to elucidate the potential synergy between S.
haematobium and HPV in cervical dysplasia. However,
VIA remains a real-world diagnostic approach in low
and middle income countries and is the recommended
WHO screening modality in these settings [17].
In conclusion, this study shows an association between
FGS, diagnosed by genital PCR, and VIA-positivity. Fur-
ther research is needed to evaluate the association be-
tween FGS and cervical dysplasia and cervical cancer. If
a causal link is established, FGS diagnosis and treatment
may provide an additional opportunity to help reduce
the burden of cervical cancer and achieve the WHO
2030 goal of cervical cancer elimination.
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